Safety and Efficacy of Rivaroxaban and Apixaban in Patients with Increased Body Mass: a Systematic Review.
Margaret M BuckAlexa M HaddonAntonietta PaneccasioDaniel J SkolodaDavid E ZimmermanAnthony J GuarascioBranden D NemecekJordan R CovveyCourtney A MonteparaPublished in: Clinical drug investigation (2021)
The literature reports similar or lower bleeding and thrombotic risk for rivaroxaban and apixaban in patients of increased body mass compared to patients of normal body mass. Future prospective controlled studies are needed to further define guidelines for use in this population.